iRhythm Technologies
IRTC
104.99
-2.21
-2.06%
iRhythm Technologies
US · IRTC
#2372 by market cap
Listed 2016
104.99
-2.21
-2.06%
Live - 5344 symbols - heartbeat 558s ago
· 2026-10-08 05:22
Pre-market
103.50
-1.42%
After-hours
104.00
-0.94%
- Market cap
- 3.46B
- P/E (TTM)i
- -249.98
- P/Bi
- 18.61
- EPSi
- -1.39
- Div yieldi
- 0.00%
- 52W posi
- 4%
Reader sentiment
Are you bullish or bearish on IRTC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 109.83% -0.12pp
- Institutions
- 376 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund79.22%
Hedge Fund22.17%
Public Company4.41%
Private Company1.65%
Individual/Insider1.50%
Government Pension Fund0.87%
VC/PE Fund0.68%
Sovereign Wealth Fund0.45%
Insurance Company0.30%
Top holders as of 2026-06-30
BlackRock
9.06% · 2.99M sh
RTW Investments, LP
6.62% · 2.18M sh
Vanguard Portfolio Management, LLC
5.81% · 1.91M sh
Vanguard Capital Management, LLC
5.15% · 1.70M sh
Artisan Partners Limited Partnership
5.04% · 1.66M sh
Millennium Management LLC
4.27% · 1.41M sh
FMR
3.62% · 1.19M sh
UBS Asset Management
3.10% · 1.02M sh
Geode Capital Management, LLC
2.68% · 881.90K sh
Eventide Asset Management, LLC
2.67% · 880.34K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 26 sells
| Name | Role | Stake |
|---|---|---|
| Quentin Blackford | Chief Executive Officer | 0.43% |
| Patrick Murphy | Chief Business & Legal Officer | 0.21% |
| Sumi Shrishrimal | Executive Vice President | 0.14% |
| Daniel Wilson | Executive VP of Corporate Development & Investor Relations | 0.11% |
| Minang Turakhia | Chief Medical & Scientific Officer and Executive VP of Product Innovation | 0.10% |
| Chad Patterson | Chief Commercial Officer | 0.10% |
| Abhijit Talwalkar | Independent Chairperson | 0.06% |
| Brian Lawrence | Executive Vice President | 0.06% |
| Bruce Bodaken | Independent Director | 0.04% |
| Mark Rubash | Independent Director | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-01 | Daniel Wilson | Executive VP of Corporate Development & Investor Relations | Open Market Disposition | -773 | $121.83 |
| 2026-08-09 | Patrick Murphy | Chief Business & Legal Officer | Open Market Disposition | -7,093 | $124.65 |
| 2026-08-09 | Quentin Blackford | Chief Executive Officer | Open Market Disposition | -26,859 | $124.65 |
| 2026-08-09 | Minang Turakhia | Chief Medical & Scientific Officer and Executive VP of Product Innovation | Open Market Disposition | -7,093 | $124.65 |
| 2026-08-09 | Chad Patterson | Chief Commercial Officer | Open Market Disposition | -7,093 | $124.65 |
| 2026-08-09 | Sumi Shrishrimal | Executive Vice President | Open Market Disposition | -5,372 | $124.65 |
| 2026-08-06 | Patrick Murphy | Chief Business & Legal Officer | Other Acquisition | +13,589 | -- |
| 2026-08-06 | Quentin Blackford | Chief Executive Officer | Other Acquisition | +48,534 | -- |
| 2026-08-06 | Minang Turakhia | Chief Medical & Scientific Officer and Executive VP of Product Innovation | Other Acquisition | +13,589 | -- |
| 2026-08-06 | Chad Patterson | Chief Commercial Officer | Other Acquisition | +13,589 | -- |
| 2026-08-06 | Sumi Shrishrimal | Executive Vice President | Other Acquisition | +9,706 | -- |
| 2026-08-02 | Chad Patterson | Chief Commercial Officer | Open Market Disposition | -2,712 | $122.12 |
| 2026-08-02 | Mervin Smith | Executive Vice President of Strategic Business Operations | Open Market Disposition | -617 | $122.12 |
| 2026-08-02 | Julianne Rodda | -- | Open Market Disposition | -2,112 | $122.12 |
| 2026-07-01 | Sean Freeman | Executive Vice President of Strategy & Corporate Development | Open Market Disposition | -918 | $124.71 |
| 2026-07-01 | Minang Turakhia | Chief Medical & Scientific Officer and Executive VP of Product Innovation | Open Market Disposition | -1,423 | $124.71 |
| 2026-06-01 | Marc Rosenbaum | Senior VP of Finance & Chief Accounting Officer | Open Market Disposition | -729 | $108.19 |
| 2026-06-01 | Sumi Shrishrimal | Executive Vice President | Open Market Disposition | -1,716 | $108.19 |
| 2026-05-28 | Quentin Blackford | Chief Executive Officer | Other Acquisition | +178 | $96.82 |
| 2026-05-28 | Sean Freeman | Executive Vice President of Strategy & Corporate Development | Other Acquisition | +273 | $96.82 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:22:02 · For reference only, not investment advice and not tailored to your situation.